Bristol Myers wins FDA priority review for Opdivo in first-line Hodgkin lymphoma

  Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the supplemental Biologics License Application (sBLA) for Opdivo® (nivolumab) in combination with doxorubicin, vinblastine and dacarbazine (AVD) for adult and pediatric (12 years and older) patients with previously untreated Stage III or IV classical Hodgkin Lymphoma (cHL). The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 8, 2026.

https://www.nasdaq.com/press-release/us-food-and-drug-administration-fda-grants-priority-review-bristol-myers-squibbs